Cell culture Sample Clauses

Cell culture. All animal procedures were approved by the University of California’s institutional IACUC protocol, in accordance with NIH policy. Neurons were prepared from C57BL/6 mice. Briefly, hippocampi were dissected from postnatal day 1 mice, dissociated using papain and trituration, and plated MEA Recordings. Extracellular recordings were obtained using a Multi Channel Systems (MCS, Reutlingen, Germany) MEA­2100 system and a 120­count multi­electrode array with 100 μm inter­electrode spacing and 30 μm electrode diameter, at a sampling frequency of 20 kHz.
AutoNDA by SimpleDocs
Cell culture. Wildtype HepG2 cells were maintained in DMEM with 5 mM glucose, 3.7 g L-1 NaHCO3, 1 mM sodium pyruvate and amino acids, supplemented with 3 mM glutamine, and 10% FBS. The cells were kept at 37 °C and 5% CO2. To test the individual and combined effects of glucose depletion and fatty acid stimulation on the free CoA level and acyl-CoA profile, the cells were incubated for 24 h in two different conditions. In condition 1 the cells were cultured in DMEM (5 mM glucose, 1 mM pyruvate supplemented with 3 mM glutamine and 10% FBS) with additional supplements 2 mM L-carnitine and 0.5 mM BSA-bound palmitate. Condition 2 was with glucose-free DMEM (no glucose, no glutamine, no pyruvate, 10% FBS) supplemented with 2 mM L-carnitine and 0.5 mM BSA-bound palmitate. After 24 h, the cells were washed twice with ice-cold PBS and harvested for further analysis. Condition 1 cells were "supplemented cells" with multiple carbon sources, while condition 2 cells were "starved cells" with fewer carbon sources.
Cell culture. 1.1. [*] vials of the primary and back-up cell line which produce the BR96 antibody [*] Confidential Treatment Requested 1.2. List of raw materials and specifications (e.g. vendor, catalog number) 1.3. Process protocols (e.g. media formulations, thaw and expansion protocol, final production tank protocol) 1.4. Historical process data (e.g. thaw and expansion data, in-process data from final production tank) 1.5. Cell-line stability data (as it becomes available)
Cell culture. JIMT-1 cells were purchased from DSMZ (Braunschweig, Germany); all other cell lines were purchased from American Type Culture Collection (Manassas, VA). HCC1419 and HCC1954 cells were maintained in RPMI with 10% fetal bovine serum (FBS); MDA- MB-361 was maintained in RPMI with 20% FBS; JIMT-1, BT474, and MDA-MB-453 were maintained in DMEM with 10% FBS; all cells were maintained in 1% penicillin/ streptomycin and cultured in humidified incubators at 37°C with 5% CO2.
Cell culture. Unless otherwise stated, solutions referred to in the text were made according to table 2.1. All solutions were made in a class II microbiological safety cabinet (MSC).
Cell culture. XXX-000X/00, X0x, xxx XXX-0X0 cells were acquired from ATCC (Manassas, VA) and maintained in DMEM (Life Technologies) supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin in a humid, 5% CO2, 37°C incubator. HEK293T and NIH-3T3 cells were transfected using Mirus TransITLT1 (Madison, WI) per the manufacturer’s protocol. N2a cells were transfected using Lipofectamine LTX (Thermo Xxxxxx Scientific) per the manufacturer’s protocol.

Related to Cell culture

  • Culture History and past behavior;

  • Product ACCEPTANCE Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User(s) shall have thirty (30) days from the date of delivery to accept hardware products and sixty (60) days from the date of delivery to accept all other Product. Where the Contractor is responsible for installation, acceptance shall be from completion of installation. Failure to provide notice of acceptance or rejection or a deficiency statement to the Contractor by the end of the period provided for under this clause constitutes acceptance by the Authorized User(s) as of the expiration of that period. The License Term shall be extended by the time periods allowed for trial use, testing and acceptance unless the Commissioner or Authorized User agrees to accept the Product at completion of trial use. Unless otherwise provided by mutual agreement of the Authorized User and the Contractor, Authorized User shall have the option to run testing on the Product prior to acceptance, such tests and data sets to be specified by User. Where using its own data or tests, Authorized User must have the tests or representative set of data available upon delivery. This demonstration will take the form of a documented installation test, capable of observation by the Authorized User, and shall be made part of the Contractor’s standard documentation. The test data shall remain accessible to the Authorized User after completion of the test. In the event that the documented installation test cannot be completed successfully within the specified acceptance period, and the Contractor or Product is responsible for the delay, Authorized User shall have the option to cancel the order in whole or in part, or to extend the testing period for an additional thirty (30) day increment. Authorized User shall notify Contractor of acceptance upon successful completion of the documented installation test. Such cancellation shall not give rise to any cause of action against the Authorized User for damages, loss of profits, expenses, or other remuneration of any kind. If the Authorized User elects to provide a deficiency statement specifying how the Product fails to meet the specifications within the testing period, Contractor shall have thirty (30) days to correct the deficiency, and the Authorized User shall have an additional sixty (60) days to evaluate the Product as provided herein. If the Product does not meet the specifications at the end of the extended testing period, Authorized User, upon prior written notice to Contractor, may then reject the Product and return all defective Product to Contractor, and Contractor shall refund any monies paid by the Authorized User to Contractor therefor. Costs and liabilities associated with a failure of the Product to perform in accordance with the functionality tests or product specifications during the acceptance period shall be borne fully by Contractor to the extent that said costs or liabilities shall not have been caused by negligent or willful acts or omissions of the Authorized User’s agents or employees. Said costs shall be limited to the amounts set forth in the Limitation of Liability Clause for any liability for costs incurred at the direction or recommendation of Contractor.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Technology Research Analyst Job# 1810 General Characteristics

  • Speech Therapy This plan covers speech therapy services when provided by a qualified licensed • loss of speech or communication function; or • impairment as a result of an acute illness or injury, or an acute exacerbation of a chronic disease. Speech therapy services must relate to: • performing basic functional communication; or • assessing or treating swallowing dysfunction. See Autism Services when speech therapy services are rendered as part of the treatment of autism spectrum disorder. The amount you pay and any benefit limit will be the same whether the services are provided for habilitative or rehabilitative purposes.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!